 Individuals with clinically-evident atherosclerotic cardiovascular disease (ASCVD) have a considerable residual risk of CVD despite intensified statin therapy and lifestyle interventions [1].
 Data source: From a multi-center prospective observational registry, the T-SPARCLE Registry, which involves 14 medical centers across all regions in Taiwan [2] . Follow-up data as of Mar 2015 was used.
 Study subjects:
 Inclusion criteria: (1) age >18 yrs; (2) with stable ASCVD (i.e., coronary atherosclerosis, cerebrovascular disease, or peripheral atherosclerosis); (3) willing to follow a NCEP Therapeutic Lifestyle Change or similar cholesterol-lowering diet; (4) if female and receiving hormone therapy, a stable regimen was maintained; (5) had at least one follow-up; and (6) signed the inform consent.
 Exclusion criteria: (1) serious heart disease or ≥NYHA functional class III heart failure; (2) life-threatening malignancy; (3) undergoing immunosuppressive therapy; (4) had experienced an acute stroke, acute coronary syndrome, or coronary revascularization procedure within the past 3 months, or scheduled to undergo coronary bypass graft surgery or valvular surgery before enrollment; (5) ASCVD unknown type; (6) taking two statins at enrollment (n=6); (7) without known information about the presence or absence of DM.
 Baseline characteristics, medical history, lipid profiles, and medication use were collected at enrollment.
 Primary outcome events: Time to the first recurrent MACE since enrollment (a composite endpoint of cardiovascular death, nonfatal stroke, nonfatal myocardial infarction, and cardiac arrest with resuscitation).
 Multivariate Cox proportional hazards models were used to identify factors associated with the recurrence of MACE, in the presence or absence of diabetes. Hazard ratio (HR) and 95% confidence interval (CI) were estimated.
 Multiple imputation technique was used to handle missing data.
 Data analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC). A two-sided p-value of <0.05 was considered statistically significant.
Methods
 A total of 3,728 ASCVD patients were included (recruited between Jan 2010 and Aug 2014), with a mean age of 65.7 (SD 11.5), 73.6% male, 87.9% with coronary heart disease, and 39.4% having DM (Table 1) . Median follow-up duration was 2.0 years.
 Compared with those without DM, diabetic ASCVD patients were older, more often female, more often treated with statins, and had a higher rate of coronary artery disease, prior intervention for coronary or peripheral artery disease, and comorbidities such as hypertension, heart failure, and chronic kidney disease (CKD).
 In the DM subpopulation, risk of MACE was significantly increased with heart failure, CKD stage 4-5 (vs. stage 1-2), increased non-HDL-C (130-160 and ≥160 mg/dL vs. <100mg/dL)), and TG level ≥250 mg/dL. Increased LDL-C levels were also associated with increased risk, but to a much less extent.
 Among non-DM individuals, history of heart failure was the only significant independent predictor of MACE.
Results
Disclosure Statements: The authors have no financial disclosures that would be a potential conflict of interest with this presentation.  Our study demonstrates that non-HDL-C, heart failure, and advanced CKD are residual risk factors for MACE in atherosclerotic patients with DM, whereas only heart failure confers a higher risk in non-DM patients.
 ASCVD patients with concomitant DM need stricter control of lipid, particularly non-HDL-C and high TG, levels.
Conclusions
 Although LDL-C has been regarded as the primary target of therapy [3] [4] [5] , it does not account for the entire cohort of atherogenic lipid particles within the systemic circulation. Non-HDL-C represents the full components of atherogenic lipids and is a surrogate marker for apolipoprotein B for routine clinical practice [6] .
 The noticeable impact of lipid abnormalities in DM patients (vs. non-DM patients) has also been suggested by the prespecified subgroup analysis in the IMPROVE-IT study [7] .
 The study is limited by the shorter patient follow-up period as the T-SPARCLE registry was implemented since 2009.
Discussion

